natgillin/translations-raw huggingface dataset:
NEVANAC is not recommended during pregnancy. 
Primjena NEVANAC-a ne preporučuje se tijekom trudnoće.
In the two studies, NEVANAC cleared inflammation at day 14 post operation in 65% and 68% of patients compared to 25% and 35% of patients on vehicle. 
U dva ispitivanja, NEVANAC je uklonio upalu na dan 14 nakon operacije kod 65% i 68% bolesnika u usporedbi sa 25% i 35% bolesnika na podlozi lijeka.
Do not use more than one drop in the affected eye(s) 3 times daily. 
U zahvaćeno oko(oči) ne ukapavajte više od jedne kapi 3 puta na dan.
It is not necessary to close and shake the bottle between administrations for both eyes. 
Nije potrebno zatvarati i protresati bočicu između primjene u jedno i primjene u drugo oko.
• Turn the closed bottle upside down and shake down once before each use. 
• Prije svake primjene okrenite zatvorenu bočicu naopako i jednom protresite prema dolje.
Rare: hypersensitivity 
Rijetko: preosjetljivost
Light yellow to light orange uniform suspension, pH 7.4 (approximately). 
Svijetložuta do svijetlonarančasta homogena suspenzija, pH 7,4 (približno).
Tiny amounts of sodium hydroxide and/or hydrochloric acid are added to keep acidity levels (pH levels) normal. 
Dodane su i vrlo male količine natrijeva hidroksida i/ili kloridne kiseline, za održavanje normalne razine kiselosti (pH vrijednosti).
Patients should be instructed to shake the bottle well before use. 
Bolesnika je potrebno uputiti da dobro protrese bočicu prije primjene.
NEVANAC has no or negligible influence on the ability to drive and use machines. 
NEVANAC ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Your doctor will advise you when you can use contact lenses again (see also “NEVANAC contains benzalkonium chloride”) 
Vaš liječnik savjetovati će Vas kada ih možete ponovno nositi (vidjeti dio “NEVANAC sadrži benzalkonijev klorid“)
CARTON FOR SINGLE BOTTLE 
KUTIJA ZA JEDNU BOČICU
NEVANAC should be used with caution in patients with known bleeding tendencies or who are receiving other medicinal products which may prolong bleeding time. 
NEVANAC treba oprezno primjenjivati u bolesnika za koje se zna da su skloni krvarenju, ili koji primaju druge lijekove koji mogu produžiti vrijeme krvarenja.
If you are worried talk to your doctor or pharmacist. 
Ukoliko ste zabrinuti, razgovarajte sa svojim liječnikom ili ljekarnikom.
In clinical trials, patients were treated for up to 21 days with NEVANAC 3 mg/ml eye drops, suspension (see section 5.1). 
U kliničkim ispitivanjima, bolesnici su liječeni do 21 dan s NEVANAC 3 mg/ml kapima za oko, suspenzijom (vidjeti dio 5.1).
Benzalkonium chloride has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. 
Zabilježeno je da benzalkonijev klorid može izazvati punktiformnu keratopatiju i/ili toksičnu ulceroznu keratopatiju.
The medicinal product should not be injected. 
Ovaj lijek ne smije se injicirati.
There may be a higher risk of corneal side effects (eye surface problems) if you have: 
Rizik od pojave nuspojava na rožnici (problemi površine oka) može biti povećan, ako ste imali:
CARTON FOR SINGLE BOTTLE 5 ml 
KUTIJA ZA JEDNU BOČICU OD 5 ml
The maximum mean aqueous humour concentrations were observed at the 1 hour time-point (nepafenac 177 ng/ml, amfenac 44.8 ng/ml). 
Maksimalne srednje vrijednosti koncentracije u očnoj vodici zapažene su nakon 1 sat (nepafenak 177 mg/ml, amfenak 44,8 ng/ml).
There is a potential for cross-sensitivity of nepafenac to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. 
Postoji potencijal za ukriženu osjetljivost nepafenaka s acetilsalicilatnom kiselinom, derivatima fenilacetatne kiseline i drugim NSAIL-ima.
Your doctor will advise you when you can use contact lenses again (see also “NEVANAC contains benzalkonium chloride”). 
Vaš liječnik savjetovati će Vas kada ih možete ponovno nositi (pogledajte dio “NEVANAC sadrži benzalkonijev klorid“).
When nepafenac is prescribed to a diabetic patient post cataract surgery to prevent macular oedema, the existence of any additional risk factor should lead to reassessment of the foreseen benefit/risk and to intensified patient monitoring. 
Prilikom propisivanja nepafenaka pacijentu s dijabetesom nakon operacije katarakte radi prevencije makularnog edema, postojanje bilo kakvog dodatnog faktora opasnosti zahtijeva ponovnu procjenu predviđenih koristi/rizika i pojačano praćenje bolesnika.
Pharmacotherapeutic group: Opthalmologicals, Anti-inflammatory agents, non-steroids, ATC code: S01BC10 
Farmakoterapijska skupina: oftalmici, protuupalni lijekovi, nesteroidni, ATK oznaka: S01BC10
In case of ocular infection, their use with antiinfectives should be undertaken with care. 
U slučaju infekcije oka, treba ih oprezno primjenjivati s antiinfektivima.
No dose adjustment is warranted in these patients. 
U tih bolesnika nije potrebno prilagođavati dozu.
The adverse reactions were obtained from clinical trials and post-marketing reports. 
Nuspojave su zabilježene kroz klinička ispitivanja i izvještaje nakon stavljanja lijeka u promet.
Topical NSAIDs may slow or delay healing. 
Topikalni NSAIL-i mogu usporiti ili odgoditi zacjeljivanje.
Nepafenac is a non-steroidal anti-inflammatory and analgesic prodrug. 
Nepafenak je nesteroidni protuupalni i analgetski predlijek.
• Do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper. 
• Kapaljkom ne dodirujte oko ili vjeđu, okolna područja ili druge površine.
There are no adequate data regarding the use of nepafenac in pregnant women. 
Nema dovoljno podataka o primjeni nepafenaka u trudnica.
Uncommon: hypertension Not known: blood pressure increased 
Manje često: hipertenzija Nepozmato: povišeni krvni tlak
Light yellow to dark orange uniform suspension, pH 6.8 (approximately). 
Svijetložuta do tamnonarančasta homogena suspenzija, pH 6,8 (približno).
Therefore, it is recommended that caution should be exercised if NEVANAC is administered concomitantly with corticosteroids, particularly in patients at high risk for corneal adverse reactions described below. 
Stoga, preporučuje se oprez kod istodobne primjene NEVANAC-a i kortikosteroida, osobito kod bolesnika kod kojih je povećan rizik pojave nuspojava na rožnici opisanih niže.
You may find that your vision is blurred for a time just after using NEVANAC. 
Vid Vam može biti zamagljen neko vrijeme nakon primjene NEVANAC-a.
Only use NEVANAC for your eyes. 
NEVANAC upotrebljavajte samo kao kapi za oko.
Contact lens wear is not recommended during the postoperative period following cataract surgery. 
Ne preporučuje se nošenje kontaktnih leća tijekom postoperativnog perioda nakon operacije katarakte.
Use of topical NSAIDs may result in keratitis. 
Primjena topikalnih NSAIL-a može uzrokovati keratitis.
Following a single dose of NEVANAC in 25 cataract surgery patients, aqueous humour concentrations were measured at 15, 30, 45 and 60 minutes post-dose. 
Nakon primjene jednostruke doze NEVANAC-a kod 25 bolesnika s operacijom katarakte mjerile su se koncentracije lijeka u očnoj vodici 15, 30, 45 i 60 minuta poslije davanja doze.
Talk to your doctor, pharmacist or nurse before using NEVANAC: - if you bruise easily or have bleeding problems or have had them in the past. 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego primijenite NEVANAC: - ako ste skloni stvaranju masnica ili imate probleme s krvarenjima ili ste ih imali u prošlosti.
If you forget to use NEVANAC 
Ako ste zaboravili primijeniti NEVANAC
Results from clinical studies indicate that NEVANAC eye drops have no significant effect on intraocular pressure. 
Rezultati kliničkih ispitivanja ukazuju na to da NEVANAC kapi za oko nemaju značajnog učinka na intraokularni tlak.
Studies in rabbits demonstrated that the topically administered nepafenac is distributed locally from the front of the eye to the posterior segments of the eye (retina and choroid). 
Ispitivanja na kunićima pokazala su da se topikalno primjenjeni nepafenak distribuira lokalno iz prednjeg dijela oka u stražnji segment oka (mrežnica i žilnica).
C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactive excretions, accounting for approximately 85% while faecal excretion represented approximately 6% of the dose. 
C-nepafenaka u zdravih dobrovoljaca, utvrđeno je da je izlučivanje mokraćom glavni put izlučivanja radioaktivno obilježenog lijeka, na što otpada oko 85% doze, dok se sa stolicom izlučuje oko 6% doze.
- if you have had repeated eye surgery within a short period of time. 
- ako imate reumatoidni artritis. - ako ste unutar kratkog vremenskog razdoblja imali više kirurških zahvata na oku.
Ex vivo, a single topical ocular dose of nepafenac was shown to inhibit prostaglandin synthesis in the iris/ciliary body (85%-95%) and the retina/choroid (55%) for up to 6 hours and 4 hours, respectively. 
Ex vivo se pokazalo da jednokratna topikalna okularna doza nepafenaka inhibira sintezu prostaglandina u šarenici/cilijarnom tijelu (85%-95%) do 6 sati i u mrežnici/žilnici (55%) do 4 sata.
If it is almost time for the next dose, leave out the missed dose and continue with the next dose of your regular routine. 
Ako ste već bliže ukapavanju slijedeće doze, izostavite onu koju ste propustili i nastavite sa sljedećom dozom prema redovitoj shemi.
The corresponding percentages in integrated analysis of the 2 studies were 15.9% in vehicle group and 4.1% in NEVANAC group, p<0.001). 
Odgovarajući postotci u integriranim analizama 2 ispitivanja bili su 15,9% u grupi s podlogom lijeka i 4,1% u grupi s lijekom NEVANAC, p<0,001).
Since NEVANAC contains benzalkonium chloride, close monitoring is required with frequent or prolonged use. 
S obzirom na to da NEVANAC sadrži benzalkonijev klorid, bolesnika treba pri čestoj ili produženoj primjeni pomno nadzirati.
Concomitant use of NEVANAC with medications that prolong bleeding time may increase the risk of haemorrhage (see section 4.4). 
Istodobna primjena NEVANAC-a i lijekova koji produljuju vrijeme krvarenja može povećati rizik od hemoragije (vidjeti dio 4.4).
A significantly greater percentage of patients achieved improvement of 15 or more letters at Day 14 and maintained the improvement through Day 90 in NEVANAC 3 mg/ml group (61.7%) compared to vehicle group (43%) in one study; the percentage of subjects was similar in the 2 treatment groups for this endpoint in the second study (48.8% in NEVANAC group and 50.5% in vehicle group). 
Značajno veći postotak bolesnika postigao je poboljšanje od 15 ili više slova u 14. danu i zadržao je poboljšanje do 90. dana u grupi koja je primala NEVANAC 3 mg/ml (61,7%) u usporedbi s grupom koja je primala podlogu lijeka (43%) u jednom ispitivanju; postoci ispitanika bili su slični u dvije liječenje grupe za ovaj ishod u drugom ispitivanju (48,8% u grupi s lijekom NEVANAC i 50,5% u grupi s podlogom lijeka).
There have been reports that ophthalmic NSAIDs may cause increased bleeding of ocular tissues (including hyphaemas) in conjunction with ocular surgery. 
Postoje izvještaji da NSAIL-i za okularnu primjenu mogu uzrokovati pojačano krvarenje očnih tkiva (uključujući hifeme) u svezi s kiruškim zahvatom na oku.
In reproduction studies performed with nepafenac in rats, maternally toxic doses ≥10 mg/kg were associated with dystocia, increased postimplantation loss, reduced foetal weights and growth, and reduced foetal survival. 
U ispitivanjima reprodukcije koja su s nepafenakom provedena u štakora, doze ≥10 mg/kg, koje su bile toksične po ženku, bile su povezane s distocijom, povećanim gubitkom nakon implantacije, smanjenom težinom i rastom fetusa te sa smanjenim preživljavanjem fetusa.
If you are breast-feeding, NEVANAC may pass into your milk. 
Ukoliko dojite, NEVANAC može prijeći u Vaše majčino mlijeko.
The second most abundant plasma metabolite was identified as 5-hydroxy nepafenac, representing approximately 9% of total radioactivity at Cmax. 
Metabolit koji je po količini drugi u plazmi, identificiran je kao 5-hidroksinepafenak koji je predstavljao oko 9% ukupne radioaktivnosti pri Cmax.
To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. 
Da bi se spriječila kontaminacija vrha kapaljke i otopine, bolesnik mora paziti da vrhom kapaljke na bočici ne dodiruje vjeđe, okolna područja ili druge površine.
NEVANAC 3 mg/ml eye drops, suspension is indicated in adults for: 
NEVANAC 3 mg/ml kapi za oko, suspenzija je indicirana u odraslih za:
What NEVANAC is and what it is used for What you need to know before you use NEVANAC How to use NEVANAC 
Što je NEVANAC i za što se koristi Što morate znati prije nego počnete primjenjivati NEVANAC Kako primjenjivati NEVANAC Moguće nuspojave
These findings indicate rapid corneal penetration. 
Ti nalazi ukazuju na to da lijek brzo penetrira kroz rožnicu.
• Hold the bottle, pointing down, between your thumb and fingers. 
• Bočicu držite između palca i prstiju, okrenutu vrhom prema dolje.
• Twist off the bottle cap. 
• Odvrnite zatvarač bočice.
In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation (see section 4.8). 
U nekih podložnih bolesnika, kontinuirana primjena topikalnih NSAIL-a može dovesti do oštećenja epitela, stanjenja rožnice, erozije rožnice, ulceracije rožnice ili perforacije rožnice (vidjeti dio 4.8).
Severity of these cases vary from non serious effects on the epithelial integrity of the corneal epithelium to more serious events where surgical interventions and/or medical therapy are required to regain clear vision. 
Težina ovih slučajeva varirala je od učinaka na epitelnu cjelovitost epitela rožnice koji nisu bili ozbiljni do ozbiljnijih nuspojava koje su zahtjevale kiruršku intervenciju i/ili terapiju lijekovima kako bi se povratila jasnoća vida.
In pregnant rabbits, a maternal dose of 30 mg/kg that produced slight toxicity in the mothers showed a statistically significant increase in the incidence of litter malformations. 
U skotnih je kunića, doza od 30 mg/kg, koju su primale ženke i koja je u njih izazvala malu toksičnost, pokazala signifikantan porast u incidenciji malformacija kod mladunčadi.
Results from clinical studies indicate that NEVANAC 3 mg/ml eye drops, suspension have no significant effect on intraocular pressure. 
Rezultati kliničkih ispitivanja ukazuju na to da NEVANAC 3 mg/ml kapi za oko, suspenzija nemaju značajnog učinka na intraokularni tlak.
Prevention and treatment of postoperative pain and inflammation associated with cataract surgery The efficacy and safety of NEVANAC 3 mg/ml in the prevention and treatment of postoperative pain and inflammation associated with cataract surgery has been demonstrated in two masked, double blind, placebo-controlled clinical trials in a total of 1339 patients. 
Prevencija i liječenje postoperativne boli i upale povezanih s operacijom katarakte Djelotvornost i sigurnost primjene NEVANAC-a 3 mg/ml u prevenciji i liječenju postoperativne boli i upale povezanih s operacijom katarakte dokazana je u dva maskirana, dvostruko slijepa, placebom kontrolirana klinička ispitivanja na ukupno 1339 bolesnika.
An acute ocular infection may be masked by the topical use of anti-inflammatory medicines. 
Akutna infekcija oka može biti prikrivena topikalnom primjenom protuupalnih lijekova.
• General side effects: vomiting, increased blood pressure. 
• Opće nuspojave: povraćanje, povišeni krvni tlak.
However, no effects on the suckling child are anticipated since the systemic exposure of the breast-feeding woman to nepafenac is negligible. 
No nije za očekivati učinak na dojenče, budući da je sistemsko izlaganje žena koje doje zanemarivo.
In these studies, study medication was initiated the day prior to surgery, continued on the day of surgery and for up to 90 days of the postoperative period. 
U tim ispitivanjima, ispitivani lijek počeo se primjenjivati dan prije operacije, nastavio na dan operacije i do 90 dana nakon operacije.
Examples of NSAIDs are: acetylsalicylic acid, ibuprofen, ketoprofen, piroxicam, diclofenac. 
NSAIL-e se primjerice ubrajaju: acetilsalicilatna kiselina, ibuprofen, ketoprofen, piroksikam,
If you are pregnant, or might get pregnant, talk to your doctor before you use NEVANAC. 
Ako ste trudni ili mislite da biste mogli ostati trudni, obratite se svom liječniku za savjet prije nego uzmete NEVANAC.
A greater percentage of patients treated with vehicle experienced a decrease in BCVA of more than 5 letters from day 7 to day 90 (or early exit) (11.5%) compared with patients treated with nepafenac (5.6%). 
Veći postotak bolesnika liječenih podlogom lijeka doživio je smanjenje u vrijednosti u najbolje korigiranoj oštrini vida (BCVA, engl. best corrected vision accurity) za više od 5 slova u danima od 7 do 90 (ili ranijeg izlaza) (11,5%) u usporedbi s bolesnicima liječenim s Nepafenakom (5,6%).
Close the bottle cap firmly immediately after use. 
Odmah nakon primjene bočicu čvrsto zatvorite sa zatvaračem.
In integrated analysis of the 2 studies, the percentage of subjects with 15 letter improvement at Day 14 and maintained to Day 90 was higher in NEVANAC 3 mg/ml group (55.4%) compared to vehicle group (46.7%, p=0.003). 
U integriranoj analizi dva ispitivanja, postotak ispitanika sa poboljšanjem od 15 slova u 14. danu i održanim poboljšanjem do 90. dana bio je veći u grupi s lijekom NEVANAC 3 mg/ml (55,4%) u usporedbi s grupom koja je primala podlogu lijeka (46,7%, p=0,003).
Patients should be instructed not to swallow NEVANAC. 
Bolesnike treba uputiti da ne gutaju NEVANAC.
In clinical studies involving over 1900 patients receiving NEVANAC 3 mg/ml eye drops, suspension, the most frequently reported adverse reactions were punctate keratitis, keratitis, foreign body sensation in eyes and eye pain which occurred in between 0.4% and 0.1% of patients. 
U kliničkim ispitivanjima koja su uključila preko 1900 bolesnika koji su primali NEVANAC 3 mg/ml kapi za oko, suspenziju, najčešće zabilježene nuspojave bile su punktiformni keratitis, keratitis, osjećaj stranog tijela u oku i bol u oku, a pojavile su se kod između 0,4% i 0,1% bolesnika.
Do not use NEVANAC unless clearly indicated by your doctor. 
Ne uzimajte NEVANAC osim na izričitu preporuku Vašeg liječnika.
If you stop using NEVANAC 
Ako prestanete primjenjivati NEVANAC
This may be up to 3 weeks (to prevent and relieve eye pain and inflammation) or 60 days (to prevent the development of macular oedema) after your operation. 
To može biti do 3 tjedna (za sprječavanje i olakšavanje boli u oku i upale) ili 60 dana (za sprječavanje razvoja makularnog edema) nakon operacije.
5 ml round low density polyethylene bottle with a dispensing plug and white polypropylene screw cap containing 5 ml suspension. 
Okrugla bočica od polietilena niske gustoće volumena 5 ml, s nastavkom za kapanje i bijelim polipropilenskim zatvaračem s navojem koja sadrži 5 ml suspenzije.
NEVANAC can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma. 
NEVANAC može utjecati na druge lijekove ili drugi lijekovi koje uzimate mogu utjecati na djelovanje NEVANAC-a, uključujući druge kapi za oko za liječenje povišenog očnog tlaka.
This may be up to 3 weeks (to prevent and relieve eye pain and inflammation) or 60 days (to prevent the development of macular oedema and to improve vision) after your operation. 
To može biti do 3 tjedna (za sprječavanje i olakšavanje boli u oku i upale) ili 60 dana (za sprječavanje razvoja makularnog edema i poboljšanje vida) nakon operacije.
Nepafenac and amfenac were not quantifiable in the urine. 
Količine nepafenaka i amfenaka nisu se mogle mjeriti u mokraći.
Wearing contact lenses is not recommended after cataract surgery. 
Nošenje kontaktih leća ne preporučuje se nakon operacije mrene.
More patients treated with NEVANAC achieved a 15 letter improvement in BCVA compared to vehicle patients, 56.8% compared to 41.9%. 
Više bolesnika liječenih s NEVANAC-om postiglo je poboljšanje od 15 slova u BCVA u usporedbi s bolesnicima koji su primali podlogu lijeka, 56,8% u usporedbi s 41,9%, p=0,019.
Do not use NEVANAC - if you are allergic to nepafenac or any of the other ingredients of this medicine (listed in section 6), - if you are allergic to other nonsteroidal anti-inflammatory drugs (NSAID) - if you have experienced asthma, skin allergy, or intense inflammation in your nose when using other NSAIDs. 
Nemojte primjenjivati NEVANAC - ako ste alergični na nepafenak ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.), - ako ste alergični na druge nesteroidne protuupalne lijekove (NSAIL) - ako ste imali astmu, kožnu alergiju, ili jaku upalu u nosu kada ste koristili druge NSAIL-e.
Topical NSAIDs should be used with caution in these patients. 
U tih bolesnika valja oprezno primjenjivati topikalne NSAIL-e.
Ocular adverse reactions in diabetic patients may occur at a higher frequency than observed in the general population (see section 4.4). 
Nuspojave na oku mogu se javljati s većom učestalosti kod bolesnika s dijabetesom, u odnosu na opću populaciju (vidjeti dio 4.4).
In these studies in which patients were dosed daily beginning one day prior to cataract surgery, continued on the day of surgery and for the first 14 days of the postoperative period, NEVANAC 3 mg/ml eye drops, suspension demonstrated superior clinical efficacy compared to its vehicle in treating postoperative pain and inflammation. 
U ovim ispitivanjima u kojima su bolesnicima primjenjivane dnevne doze počevši jedan dan prije operacije katarakte, nastavljane na dan operacije i tijekom prvih 14 dana postoperativnog perioda, NEVANAC 3 mg/ml kapi za oko, suspenzija pokazao je superiornu kliničku djelotvornost u usporedbi s podlogom lijeka u liječenju postoperativne boli i upale.
Clinical trial experience for the long-term use of NEVANAC for the prevention of macular oedema post cataract surgery in diabetic patients is limited. 
Iskustvo kliničkih ispitivanja dugotrajne primjene NEVANAC-a za prevenciju makularnog edema nakon operacije katarakte je ograničeno.
In these studies, study medication was initiated the day prior to surgery, continued on the day of surgery and for up to 2-4 weeks of the postoperative period. 
U tim se ispitivanjima započelo s primjenom ispitivanog lijeka jedan dan prije kirurškog zahvata, nastavilo na dan operacije te još do 2-4 tjedna tijekom postoperativnog perioda.
After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. 
Nakon topikalnog doziranja u oko, nepafenak penetrira kroz rožnicu i hidrolaze ga u očnom tkivu pretvaraju u amfenak, nesteroidni protuupalni lijek.
Do not use a double dose to make up for a missed dose. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili propuštenu dozu.
Patients should be instructed to avoid sunlight during treatment with NEVANAC. 
Bolesnike je potrebno uputiti da tijekom liječenja s lijekom NEVANAC izbjegavaju sunčevo svjetlo.
In 1 double-masked, randomised vehicle-controlled study, conducted in diabetic retinopathy patients, a significantly greater percentage of patients in the vehicle group developed macular oedema (16.7%) compared to patients treated with NEVANAC (3.2%). 
U 1 dvostruko maskiranom, randomiziranom, podlogom lijeka kontroliranom ispitivanju, provedenom u bolesnika s dijabetičkom retinopatijom, značajno veći postotak bolesnika u grupi s podlogom lijeka razvio je makularni edem (16,7%) u usporedbi s bolesnicima liječenim NEVANAC-om (3,2%).
This medicine contains 0.25 mg benzalkonium chloride in each 5 ml which is equivalent to 0.05 mg/ml. 
Ovaj lijek sadrži 0,25 mg benzalkonijevog klorida u svakih 5 ml, što odgovara 0,05 mg/ml.
This medicine contains 0.15 mg benzalkonium chloride in each 3 ml which is equivalent to 0.05 mg/ml. 
Ovaj lijek sadrži 0,15 mg benzalkonijevog klorida u svakih 3 ml, što odgovara 0,05 mg/ml.